Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | terminated | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02106091 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | terminated | Phase 1 | 16 | Affimed GmbHINDUSTRY | 4 | Jun 18, 2019 | clinicaltrials |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | terminated | N/A | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 1 | Yvonne EfeberaOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | terminated | Phase 2 | 81 | Seagen Inc.INDUSTRY | 1 | May 17, 2019 | clinicaltrials |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | terminated | Phase 1 / Phase 2 | 8 | Mayo ClinicOTHER | 1 | May 17, 2019 | clinicaltrials |
| NCT02613182 | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis(OLE) | terminated | Phase 2 | 34 | Prothena Biosciences Ltd.INDUSTRY | 1 | May 16, 2019 | clinicaltrials |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | terminated | Phase 2 | 10 | Gilead SciencesINDUSTRY | 1 | May 14, 2019 | clinicaltrials |
| NCT01927718 | Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | terminated | N/A | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | terminated | Phase 1 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT02568683 | Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | terminated | Phase 1 / Phase 2 | 10 | Gilead SciencesINDUSTRY | 2 | Apr 17, 2019 | clinicaltrials |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | terminated | Phase 3 | 1,418 | Hoffmann-La RocheINDUSTRY | 29 | Apr 12, 2019 | clinicaltrials |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | terminated | Phase 2 | 3 | St. Jude Children's Research HospitalOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice(N1) | terminated | — | 23 | CureOneOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | terminated | Phase 2 | 80 | Prothena Biosciences Ltd.INDUSTRY | 10 | Mar 26, 2019 | clinicaltrials |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | terminated | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 15, 2019 | clinicaltrials |
| NCT01948180 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma(CITADEL) | terminated | Phase 2 | 15 | Cell Medica LtdINDUSTRY | 4 | Mar 13, 2019 | clinicaltrials |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | terminated | Phase 2 | 24 | Seagen Inc.INDUSTRY | 2 | Mar 11, 2019 | clinicaltrials |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | terminated | Phase 1 / Phase 2 | 26 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma | terminated | Phase 2 | 24 | Sirtris, a GSK CompanyINDUSTRY | 2 | Feb 27, 2019 | clinicaltrials |
| NCT03379493 | Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | terminated | Phase 1 | 4 | Eureka Therapeutics Inc.INDUSTRY | 1 | Feb 4, 2019 | clinicaltrials |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | terminated | Phase 2 / Phase 3 | 85 | Dr. med. Lars-Olof MueggeOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | terminated | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | terminated | Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | terminated | Phase 1 / Phase 2 | 6 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 14 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)(BENEFIT) | terminated | Phase 2 | 21 | Centre Leon BerardOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02061449 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | terminated | Phase 1 | 3 | NYU Langone HealthOTHER | 1 | Dec 24, 2018 | clinicaltrials |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | terminated | Phase 1 | 50 | PlexxikonINDUSTRY | 1 | Dec 24, 2018 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | terminated | Phase 3 | 147 | AB ScienceINDUSTRY | 2 | Dec 19, 2018 | clinicaltrials |
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors | terminated | Phase 1 | 53 | MedImmune LLCINDUSTRY | 3 | Dec 19, 2018 | clinicaltrials |
| NCT01374217 | Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma | terminated | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | terminated | Phase 2 | 105 | Gilead SciencesINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Bridalveil) | terminated | Phase 3 | 475 | Gilead SciencesINDUSTRY | 15 | Nov 16, 2018 | clinicaltrials |
| NCT00038883 | Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies | terminated | N/A | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT02376933 | Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer | terminated | N/A | 11 | University of ArizonaOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038779 | Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States | terminated | N/A | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2018 | clinicaltrials |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction(PrE1003) | terminated | Phase 1 / Phase 2 | 63 | PrECOG, LLC.OTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01676961 | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy | terminated | Phase 2 | 5 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma(rev/abraxane) | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00809341 | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 25, 2018 | clinicaltrials |
| NCT00413959 | VELCADE,Rituximab,Cyclophosphamide and Decadron(VRCD) | terminated | Phase 2 | 12 | Oncology Specialists, S.C.OTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02602067 | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients(Tenatumomab) | terminated | Phase 1 | 2 | sigma-tau i.f.r. S.p.A.INDUSTRY | 2 | Sep 18, 2018 | clinicaltrials |
| NCT01663571 | STAT3 in T Cells: At The Crossroads of Inflammation and Cancer | terminated | — | 35 | NYU Langone HealthOTHER | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 19 | University Health Network, TorontoOTHER | 2 | Sep 13, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 27, 2019source: clinicaltrials